# Intralesional PV-10 Chemoablation of Metastatic Melanoma

> **NCT00219843** · PHASE1 · COMPLETED · sponsor: **Provectus Pharmaceuticals** · enrollment: 20 (—)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** PV-10 (rose bengal disodium, 10%)

## Key facts

- **NCT ID:** NCT00219843
- **Lead sponsor:** Provectus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** 20 (—)
- **Last updated:** 2007-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219843, "Intralesional PV-10 Chemoablation of Metastatic Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00219843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*